iNtRON Biotechnology Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

iNtRON Biotechnology hat ein Gesamteigenkapital von ₩93.1B und eine Gesamtverschuldung von ₩0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen ₩98.3B bzw. ₩5.2B.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

₩0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	₩57.31b
Eigenkapital	₩93.11b
Gesamtverbindlichkeiten	₩5.16b
Gesamtvermögen	₩98.27b

Jüngste Berichte zur Finanzlage

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

May 03

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

Jan 05

Recent updates

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

May 03

We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Mar 24

Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?

Feb 28

iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?

Jan 31

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

Jan 05

What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You

Dec 10

iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years

Nov 26

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: A048530Die kurzfristigen Aktiva des Unternehmens (₩61.0B) übersteigen seine kurzfristigen Passiva (₩4.6B).

Langfristige Verbindlichkeiten: A048530Die kurzfristigen Vermögenswerte des Unternehmens (₩61.0B) übersteigen seine langfristigen Verbindlichkeiten (₩558.7M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: A048530 ist schuldenfrei.

Schulden abbauen: A048530 hat keine Schulden im Vergleich zu vor 5 Jahren, als das Verhältnis von Schulden zu Eigenkapital 9.6% betrug.

Schuldendeckung: A048530 hat keine Schulden und muss daher nicht durch den operativen Cashflow gedeckt werden.

Zinsdeckung: A048530 hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

iNtRON Biotechnology Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

Recent updates

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Full year 2023 earnings released: ₩292 loss per share (vs ₩168 profit in FY 2022)

Intron Biotechnology, Inc. Announces New Drug Part Secures A Potent Anti-Cancer Candidate, PHAGERIA®, with Broad Antimicrobial Activity Against ETBF (Enterotoxigenic B. Fragilis), A Harmful Microbe Associated with Colorectal Cancer

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment improves as stock rises 30%

iNtRON Biotechnology Identifies Prophage and Jamphage in the Pancreatic Cancer Related Microbiome

Full year 2022 earnings released: EPS: ₩168 (vs ₩288 in FY 2021)

Investor sentiment deteriorates as stock falls 15%

iNtRON Biotechnology, Inc. Confirms the Efficacy of BAL200, A Novel Endolysin Biologic for Inhalational Anthrax

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Price target decreased to ₩16,400

iNtRON Developed Advanced Bacteriophage Engineering Platform Technology Based on Modified Random Mutagenesis

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

iNtRON Develops New CRISPR/Cas Technology Specific for Bacteriophage as PHAGERUS® Platform

iNtRON Biotechnology, Inc. Confirms Efficacy of Cdl200 Against CDI Clinical Isolates

iNtRON Biotechnology, Inc. (KOSDAQ:A048530) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

iNtRON Biotechnology Completes GLP-TOX Studies of BAL200

Price target decreased to ₩16,400

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

iNtRON Biotechnology, Inc. announced that it has received KRW 40 billion in funding

We Think iNtRON Biotechnology (KOSDAQ:048530) Can Stay On Top Of Its Debt

We Believe iNtRON Biotechnology's (KOSDAQ:048530) Earnings Are A Poor Guide For Its Profitability

Does iNtRON Biotechnology's (KOSDAQ:048530) Share Price Gain of 81% Match Its Business Performance?

iNtRON Biotechnology, Inc., Annual General Meeting, Mar 25, 2021

iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) Stock Is Going Strong: Is the Market Following Fundamentals?

iNtRON Biotechnology (KOSDAQ:048530) Has A Rock Solid Balance Sheet

New 90-day high: ₩23,000

Investor sentiment improved over the past week

Market bids up stock over the past week

What iNtRON Biotechnology, Inc.'s (KOSDAQ:048530) 26% Share Price Gain Is Not Telling You

New 90-day high: ₩17,050

iNtRON Biotechnology (KOSDAQ:048530) Share Prices Have Dropped 49% In The Last Five Years

New 90-day low: ₩13,800

New 90-day high - ₩18,100

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen